# HVTN

**Full Group Meeting** 









CONTENTS —	
Mobile App and Conference Website	1
Meeting Details	1
General Information	3
Special Sessions	3
HVTN Scientific Leadership  Development Program	4
Tuesday, April 30th	5
Wednesday, May 1st	5
Thursday, May 2nd	7
Friday, May 3rd	12
Acronym Glossary	14
Notes	17
At-A-Glance	18
Maps	Back

#### PROGRAM KEY-

Use the Key below to help navigate the Meeting Program.



#### **MOBILE APP**



A companion to the printed program, this intuitive app includes features that allow you explore, organize and customize your meeting experience. Search for speakers, meeting topics, special sessions, etc. and plan ahead using the personal scheduling feature.

#### To Download the App:

- Scan this QR code with your mobile device. This will take you to straight to the app.
- 2. Install the "HVTN Meetings" app.
- 3. Click on Passphrase icon (lower right corner) and enter "hvtnfgm2024" in the passphrase field.
- 4. "Download guide."



The app is available for download to all attendees. For more information, FAQ and tips, visit: tinyurl.com/hvtnmeeting

#### **CONFERENCE WEBSITE**

To access the conference website and stream the sessions, please scan the QR code to the right and use the case sensitive password "HVTNFGM2024" you can also access the conference website at www.hvtnfgm.org



#### **MEETING DETAILS**

#### MEETING VENUE

Omni Shoreham Hotel 2500 Calvert Street NW Washington, D.C. 20008

Phone: 202.234.0700

Check-In Time: 3:00 pm Check-Out Time: 12:00 pm

https://www.omnihotels.com/hotels/washington-dc-shoreham

#### MEETING REGISTRATION DESK

The HVTN registration desk will be located in the West Lobby near the stairs to Ambassador and Regency Ballrooms.

Tuesday, April 30th	4:00 – 8:00 pm
Wednesday, May 1st	6:45 am – 5:30 pm
Thursday, May 2nd	6:30 am – 6:30 pm
Friday, May 3rd	7:00 am – 1:30 pm

#### NAME BADGES

All registered meeting attendees will be issued a meeting name badge when they check-in. Name badges are required for all meeting attendees. Please be sure to wear your name badge at all times when attending conference-related functions. If you do not have a name badge, or you have lost yours, please return to the registration desk and another badge will be issued.

#### PLENARY SPEAKER CHECK-IN

All presenting plenary speakers must check in at the AV table in the rear of the Regency Ballroom at least 30 minutes prior to their plenary session to hand in their presentation slides, unless they have already done so. The AV technician will be available:

AV TECHNICIAN HOURS	
Wednesday, May 1st 7:15 am - 4:00 pm	
Thursday, May 2nd	7:00 am - 6:30 pm
Friday, May 3rd	7:00 am – 12:30 pm

#### **HVTN RECEPTION**

Please join your colleagues at the HVTN Reception; there will be food and beverages. We look forward to seeing you there!

Ambassador Ballroom	
Wednesday, May 1st	7:00 – 10:00pm



#### CONFIDENTIALITY

Just a reminder—information shared in plenaries and all other sessions is confidential.

#### **MEETING DETAILS**

#### PROGRAM-AT-A-GLANCE

For an overview of the meeting program, please refer to the Program-at-a-Glance on pages 18-25. The sessions are color coded to indicate plenary sessions, open sessions, closed sessions, interpretation, live streaming and catering.

#### **MEALS**

Breakfast, morning break, lunch, and afternoon break will be served in the Ambassador Ballroom. If you are attending a breakfast or lunch session, there will be a buffet in or near your meeting room. Attendees will be on their own for lunch Friday unless they have a session that begins at or after 12:30pm.

WEDNESDAY, MAY 1ST	
Breakfast	6:45 – 8:30 am
Morning break	10:30 – 11:00 am
Lunch	12:30 – 2:00 pm
Afternoon break	4:00 – 5:00 pm

THURSDAY, MAY 2ND	
Breakfast	6:45 – 8:30 am
Morning break	10:15 – 10:45 am
Lunch	12:45 – 2:00 pm
Afternoon break	3:45 – 4:10 pm

FRIDAY, MAY 3RD	
Breakfast	6:30 – 8:30 am
Morning break	11:00 – 11:15 am

#### PLENARY PRESENTATIONS

Regency Ballroom

WEDNESDAY, MAY 1ST	
Non-Technical Day 1 Plenary Highlight 8:15 – 8:30 am	
Plenary 1	8:30 – 10:30 am
Plenary 2	11:00 am – 12:30 pm

THURSDAY, MAY 2ND	
Non-Technical Day 2 Plenary Highlight	8:15 – 8:30 am
The HVTN at 25 Years of Age	8:30 – 8:45 am
Plenary 3	8:45 am – 10:15 pm
Plenary 4	10:45 am – 12:45 pm
HVTN Awards	2:00 – 2:20 pm
Plenary 5 pt 1	2:20 - 3:45 pm
Plenary 5 pt 2	4:10 – 5:00 pm
Poster Session Flash Talks	6:00 – 6:30 pm
Poster Session/RAMI Scholar Poster Session Reception	6:30 – 7:30 pm

FRIDAY, MAY 3RD	
Plenary 6	8:00 – 9:05 am
HIV Vaccine Trials Network Wizard Award	d 9:05 – 9:35 am
Plenary 7	9:35 am – 11:00 am
Plenary 8	11:15 am – 12:30 pm

Please note, a majority of the plenary presentation slides will be available online following the conclusion of the meeting. You will be able to access these slides on the Members website at:

https://fredhutch.sharepoint.com/sites/HVTN/hvtn-conference/ SitePages/2024-Full-Group-Meeting.aspx

#### **GENERAL QUESTIONS AND COMMENTS**

Do you have plenary questions and missed your chance to ask them? Scan the QR code to the right and submit your questions online.



#### **GENERAL INFORMATION**

#### MEETING EVALUATIONS

At the conclusion of the meeting, registered participants will be asked to complete a brief online evaluation. The link will be sent to the email address you provided at registration. Your feedback is appreciated as it better prepares our events staff for future meetings.

#### **INTERNET ACCESS**

Wi-Fi will be provided throughout the Omni Shoreham Hotel meeting spaces.

- 1. View Available Networks
- 2. Connect to "Omni Meeting" Network
- 3. Open up your web browser and you'll see the splash page
- 4. Enter access Code: FGM2024
- 5. Click Connect

#### INTERPRETATION SERVICES

Infinity Translations will provide simultaneous Portuguese and Spanish translation for all plenary sessions as well as many sessions in the Empire Ballroom. Interpretation headsets can be picked up from Infinity Translations in the Regency Gallery and Empire Foyer.

#### SPECIAL SESSIONS

#### **HVTN FOR FIRST TIMERS**

Is this your first time attending a major meeting hosted by the HIV Vaccine Trials Network?

This session helps to ensure attendees understand the HVTN and how it is designed to support site activity. Attendees will also learn how to build capacity for participating in the meeting, as for many this is their first scientific conference. Breakfast will be served in the Empire Ballroom.

EMPIRE BALLROOM	
Wednesday, May 1st 7:15 - 8:15 am	

#### POSTER SESSION

Meet, mingle, and learn about innovative HIV & COVID-19 science being conducted by researchers, including the rising generation of researchers – our RAMP Scholars. Join us for a fun event to learn about their work.

REGENCY BALLROOM	
Thursday, May 2nd	6:00 - 7:30 pm

#### RED RIBBON REGISTRY HELP DESK

This will be a space to troubleshoot Red Ribbon Registry issues with site users. Site users can drop in with any questions, comments and concerns regarding use of the Red Ribbon Registry.

REGENCY GALLERY				
Wednesday, May 1st Morning & Afternoon Break				
Thursday, May 2nd Morning Break				

#### DAIDS REGULATORY SUPPORT CENTER

Got Questions? DAIDS Regulatory Support Center (RSC) has the answers. The DAIDS RSC will be available to answer your questions on May 1 and 2, 2024. Specialists will be at the DAIDS RSC Information Booth to share information on topics such as Safety Reporting and Protocol Registration processes via NCRMS, Regulatory activities, Protocol Development, Trial Master Files, and more. Questions can be submitted ahead of time to DAIDSRSCMgrs@tech-res.com and many resources are also available at https://rsc.niaid.nih.gov/.

REGENCY GALLERY				
Wednesday, May 1st 9:00 am - 5:00 pm				
Thursday, May 2nd 9:00 am - 5:00 pm				

#### MICROSOFT TEAMS REFRESHER DROP-IN

In these drop-in sessions, we will go over Microsoft Teams and how to use this program with the HVTN, especially on writing and protocol teams, highlighting collaborative editing of documents.

EXECUTIVE ROOM				
Thursday, May 2nd 10:15 - 10:45 AM				
Thursday, May 2nd 12:45 - 1:00 PM				
Thursday, May 2nd 3:45 - 4:10 PM				

#### **HVTN AWARDS**

Jim Kublin, MD, MPH will host the annual HVTN Awards where recipients will be recognized for their service and dedication.

Service Award and Citizenship Award Presented By: Dishiki Kalonji & Sri Edupuganti The Service Award honors those who have met a particular challenge in their work, and whose creative response has strengthened the Network. The Citizenship Award honors those who, in the performance of their duties and activities, exemplify the best qualities of Network citizenship.

#### Mentoring Award Presented By: Jim Kublin

Honors an individual deserving special recognition for excellence in mentoring researchers and/or other research staff.

Octavio Valente, Jr. Volunteer Service Award Presented By: Rafael Gonzalez This service award is given to a CAB member who has demonstrated exemplary leadership and dedication in the HVTN.

Wakefield Outstanding Dedication Awards Presented By: Louis Shackelford This award recognizes the recipient's steadfast passion for HIV research, shaping HIV vaccine education and research efforts in their local community, at a local research site, nationwide, or globally.

Bonnie Mathieson Young Investigator Award Presented By: Larry Corey Presented annually, to recognize young investigators who have published an outstanding first author, co-first author, or senior author paper with the HVTN in the previous year.

#### Gita Ramjee Award Presented By: Larry Corey

This award recognizes outstanding commitment and contributions during one's career to HIV prevention research and the HVTN

REGENCY BALLROOM				
Thursday, May 2nd	2:00 - 2:20 PM			

#### HIV VACCINE TRIALS NETWORK WIZARD AWARD

Larry Corey, MD, will present the "HIV Vaccine Trials Network Wizard Award" to Hugh Auchincloss, MD, retiring Deputy Director of NIAID, for his tireless support during and after the COVID-19 epidemic. In his absence, Jeanne Marrazzo, MD MPH, Director of NIAID, will accept the award and also give a presentation tentatively entitled "Update from the Director."

REGENCY BALLROOM			
Friday, May 3rd 9:05 - 9:35 AM			

# HVTN SCIENTIFIC LEADERSHIP DEVELOPMENT PROGRAM

Our mission is to build the next generation of diverse scientists to lead HIV vaccine clinical trials around the world.

We congratulate our 2024 awardees, who will receive support for one year to complete an HVTN-mentored research project.

Applications for next year's program will open during Summer 2024; more information can be found at <a href="https://www.hvtn.org/scientific-programs/scientific-leadership-development.html">https://www.hvtn.org/scientific-programs/scientific-leadership-development.html</a> or by corresponding with Alison Roxby, MD at <a href="mailto:aroxby2@fredhutch.org">aroxby2@fredhutch.org</a>.

#### 2024 Awardees

Jorge Soler, PhD, MPH New York Blood Center New York City, USA

Mentor: Dr. Hong Van Tieu

Jaspreet Banga, MD, MPH Beth Israel Deaconess Medical Center Boston, USA

Mentor: Dr. Kathryn Stephenson

Logashvari Naidoo, MBChB South African Medical Research Council Durban, South Africa

Mentor: Dr. Elizabeth Spooner

Zinhle Zwane, MBChB Setshaba Research Centre Soshanguve, South Africa

Mentor: Dr. Khatija Ahmed

Ferdinando Menezes, MD University of São Paulo São Paulo, Brazil

Mentor: Dr. Esper Kallas

Ethel Kamuti, MD, MBA Centre for Infectious Disease Research Zambia Lusaka, Zambia

Mentor: Dr. Monde Muyoyeta













Interested in learning more? Attend these open breakout sessions!

#### Thursday, May 2<sup>ND</sup>

Protocol Chair & Co-Chair Interest Session 1:00 - 1:30 pm Congressional Room A&B Scientific Leadership Development Program Overview 1:30 - 2:00 pm Congressional Room A&B

#### TUESDAY, APRIL 30TH

#### Open Registration & Badge Pick-Up

6:00 - 8:00 pm

West Registration Desk in the West Lobby (on the main floor of the hotel)

#### WEDNESDAY, MAY 1ST

#### Open Registration & Badge Pick-Up

6:45 am - 5:30 pm

West Registration Desk in the West Lobby (on the main floor of the hotel)

**BREAKFAST** 

6:45 - 8:30 AM

6:45 - 8:30 am

Ambassador Ballroom

#### **BREAKOUT SESSIONS**

7:15 - 8:15 AM

Breakfast will be served in or near the meeting room

#### HVTN 142/VIR 1388\_V01 Site Meeting

7:15 - 8:15 am

Palladian Ballroom

Closed

Session chair: Carrie Sopher

#### AMP Transmission Bottleneck Writing Team

7:15 - 8:15 am

Forum Room

Closed

Session chair: Mindy Miner

#### **BREAKOUT SESSIONS**

7:15 - 8:15 AM

Breakfast will be served in or near the meeting room

#### HVTN for First Timers ○ ★

7:15 - 8:15 am

**Empire Ballroom** 

Open

Session chair: Louis Shackelford

#### **Efficacy Trials Working Group**

7:15 - 8:15 am

**Executive Room** 

Open

Session chairs: Holly Janes &

Susan Buchbinder

#### NON-TECHNICAL ● ★

8:15 - 8:30 AM

#### Day 1 Plenary Highlight

8:15 - 8:30 am

Regency Ballroom

Session chair: Lindsey Baden, MD Harvard University

PLENARY 1 ● ★

8:30 - 10:30 AM

#### Road to Combo-AMP

8:30 - 10:30 am Regency Ballroom

Session chairs: Ted Pierson, PhD/Rafael Gonzalez National Institute of Health/ Fred Hutch

#### HVTN's Strategic Approach to bnAb Regimen Selection

8:30 - 8:45

Dan Barouch, MD, PhD Harvard University

#### Potency & Coverage of Abs

8.45 - 9.00

David Montefiori, PhD **Duke University** 

#### **HVTN Studies & PK Results**

9:00 - 9:15

Yunda Huang, PhD & Georgia Tomaras, PhD

Fred Hutch & Duke University

#### **HVTN Trials**

9:15 - 9:30

Huub Gelderblom, MD, PhD & Hyman Scott, MD, MPH

Fred Hutch & BridgeHIV

#### The Pathway to an Infant Efficacy Trial

Glenda Gray, MBBCh, DSc & Holly Janes, PhD South African Medical Research Council & Fred Hutch

#### Long Acting PrEP... in Context a View from HPTN

9:45 - 10:00

Mike Cohen, MD

University of North Carolina

#### The Economics of bnAbs for Prevention of HIV

10:00 - 10:15

Blythe Adamson, PhD, MPH

Infectious Economics

#### Questions & Answers/Discussion

10:15 - 10:30

#### MORNING BREAK

10:30 - 11:00 AM

10:30 - 11:00 am **Ambassador Ballroom** (just across the hall from the plenary session)

5

PLENARY 2 • \*

11:00 AM- 12:30 PM

#### The Impact of bnAbs on Our Future?

11:00 - 12:30 pm Regency Ballroom

Session Chairs: Michele Andrasik, PhD/Sally

Bock/Louis Shackelford, MPH/

S. Wakefield Fred Hutch

#### Can bnAbs Address the Global Pandemic?

11:00 - 11:10

Chris Beyrer, MD & Nyaradzo Mgodi, MBChB, MMed Duke University & University of Zimbabwe Clinical Trials Research Center (UZ-CTRC)

#### Open Discussion Facilitated by Chairs

11:10 - 11:25

### How People Living with HIV are Shaping the Future of Prevention

11:25 - 11:35

Daniel Driffin, PhD, MPH & Hyman Scott, MD, MPH Fred Hutch & BridgeHIV

#### Open Discussion Facilitated by Chairs

11:35 - 11:50

### Consumer Messaging Data & Study Participant Perspectives

11:50 - 12:05

Sally Bock/Linda-Gail Bekker, MBChB, DTMH, DCH,

FCP(SA)/Jorge Sanchez, MD, MPH Fred Hutch/Desmond Tutu/CITBM

#### Open Discussion Facilitated by Chairs

12:05 - 12:30

LUNCH 12:30 – 2:00 PM

12:30 - 2:00 pm Ambassador Ballroom

#### BREAKOUT SESSION

1:00 - 2:00 PM

Lunch will be served in the meeting room

#### Breaking Down the Science Luncheon • \*

1:00 - 2:00 pm Empire Ballroom

Open Session Chair: Rafael Gonzalez

#### BREAKOUT SESSIONS

1:00 - 2:00 PM

Lunch will be served in or near the meeting room

#### **NEC Meeting**

1:00 – 2:00 pm Executive Room

Closed Session chairs: Sri Edupuganti &

Dishiki Kalonji

#### FDA Engagement Meeting

1:00 – 2:00 pm Congressional Room A&B

Closed Session chair: Craig Sturgeon

## INVESTIGATORS MEET THE PROFESSORS SEMINAR:

2:00 - 4:00 PM

All Investigators should join their assigned meeting room at 2:00 pm.

Last names/family names beginning with A-M, please go to the Regency Ballroom.

Last names/family names beginning with N-Z, please go to the Palladian Ballroom.

Each investigator will have an hour with these researchers.

Adventures in Vaccine Development Dan Barouch, MD, PhD Harvard University

Correlating Structure with Vaccine Boosting Priyamvada Acharya, PhD Duke University

#### **BREAKOUT SESSIONS**

2:00 - 3:00 PM

#### General Community Session • \*

2:00 - 3:00 pm Empire Ballroom

Closed Session chair: Rafael Gonzalez

#### **HVTN Lab Center Team Review**

2:00 - 3:00 pm Executive Room

Closed Session chair: Katy Dougherty

#### **HVTN-RAB** Meeting

2:00 – 3:00 pm Congressional Room A&B

Closed Session chair: Meg Trahey

#### **BREAKOUT SESSION**

3:00 - 4:00 PM

#### CAB Breakout Session • \*

3:00 - 4:00 pm Empire Ballroom

Closed Session chair: Kagisho Baepanye

#### **AFTERNOON BREAK**

4:00 - 5:00 PM

4:00 – 5:00 pm Ambassador Ballroom

#### **BREAKOUT SESSIONS**

4:00 - 5:00 PM

## Community Stakeholder Conversation: bnAbs & the Way Forward ○ ★

4:00 - 5:00 pm Empire Ballroom

Closed Session chairs: Sally Bock &

Louis Shackelford

#### **UFOSApNP Concept Team Meeting**

4:00 – 5:00 pm Col Closed Ses

Congressional Room A&B Session chairs: Preston Church &

Briana Furch

#### **BREAKOUT SESSIONS**

4:00 - 5:00 PM

#### Social & Behavioral Sciences Working Group

4:00 - 5:00 pm Cabinet Room

Open Session chair: Michele Andrasik

#### **BREAKOUT SESSIONS**

4:30 - 5:30 PM

#### **HVTN 313 Site Meeting**

4:30 - 5:30 pm Palladian Ballroom

Closed Session chair: Kylie McCloskey

#### HVTN 141/HPTN 105 Protocol Team Meeting

4:30 - 5:30 pm Executive Room

Closed Session chair: Manuel Villaran

#### **HVTN 135 Core Writing Team**

4:30 – 5:30 pm Forum Room

Closed Session chair: Will Hahn

#### **BREAKOUT SESSIONS**

5:00 - 6:00 PM

#### **HVTN SRC Co-Chairs Meeting**

5:00 - 6:00 pm Cabinet Room

Closed Session chair: Sam Robinson

#### **BREAKOUT SESSIONS**

5:00 - 7:00 PM

#### Research & Mentorship Program (RAMP) Career Opportunities in HIV Vaccine & Prevention Research

5:00 – 7:00 pm Empire Ballroom

Closed Session chair: Linda Oseso

#### **BREAKOUT SESSION**

5:30 - 6:30 PM

#### **Concept Committee Meeting**

5:30 - 6:30 pm Executive Room

Open Session chair: Troy Martin

#### **BREAKOUT SESSIONS**

5:30 - 7:00 PM

#### **Ubuntu Writing Team Meeting**

5:30 – 7:00 pm Forum Room

Closed Session chair: Asa Tapley

#### **HVTN RECEPTION**

7:00 – 10:00 pm Ambassador Ballroom

Please join your colleagues at the HVTN Reception; there will be food and beverages.

#### THURSDAY, MAY 2ND

#### Open Registration & Badge Pick-Up

6:30 am – 6:30 pm West Registration Desk in the West Lobby

(on the main floor of the hotel)

**BREAKFAST** 

6:45 - 8:30 AM

6:45 - 8:30 am Aml

Ambassador Ballroom

#### **BREAKOUT SESSIONS**

7:15 - 8:15 AM

Breakfast will be served in or near the meeting room

#### CER Breakout Session • \*

7:15 – 8:15 am Empire Ballroom

Closed Session chair: Tshidi Malefo

#### **HVTN 301 Site Meeting**

7:15 – 8:15 am Palladian Ballroom

Closed Session chair: India Tindale

#### **HVTN 312 Site Meeting**

7:15 – 8:15 am Executive Room

Closed Session chair: Preston Church

#### Viral Escape from VRC01 Writing Team

7:15 – 8:15 am Cabinet Room

Closed Session chair: Carolyn Williamson

## CoVPN 3008 TB Substudy Protocol Team Meeting

7:15 – 8:15 am Forum Room

Closed Session chair: Carrie Sopher

#### **BREAKOUT SESSIONS**

7:15 - 8:15 AM

Breakfast will be served in or near the meeting room

#### **HVTN Mentor Workshop**

7:15 – 8:15 am Congressional Room A&B

Open Session chair: Linda Oseso

#### NON-TECHNICAL ● ★

8:15 - 8:30 AM

#### Day 2 Plenary Highlight

8:15 – 8:30 am Regency Ballroom

Session chair: Julie McElrath, MD, PhD
Fred Hutch

rrea nutcri

THE HVTN AT 25 ●★ YEARS OF AGE

8:30 - 8:45 AM

The HVTN at 25 Years of Age, Where is it Going?

8:30 - 8:45 am

Regency Ballroom

Session chair: Carl Dieffenbach,PhD

National Institute of Allergy & Infectious Diseases

PLENARY 3 ● ★

8:45 - 10:15 AM

Data Forum 1

8:45 - 10:15 am Regency Ballroom

Session chairs: LaTonya Williams, PhD/

Derrick Mapp

Duke University/BridgeHIV & CAB/GCAB representative on Scientific Review Committee

HVTN 300 – B cell Sequencing & Nojima Culture mAb Responses

8:45 - 9:05

Lindsey Baden, MD & Barton Haynes, MD Harvard University & Duke University

HVTN 302 - BCR sequencing

9:05 - 9:20

Ollivier Hyrien, PhD

Fred Hutch

HVTN 108 – IgG & Fc Receptor Genetic Variation Associates with Functional Ab Responses

9:20 - 9:35

Justin Pollara, PhD

**Duke University** 

HVTN 805/HPTN 093/A5390 – Cell Phenotyping & ICS

9:35 - 9:50

Shelly Karuna, MD, MPH

Fred Hutch

HVTN 119 - Focus on T cell Gag Responses

9:50 - 10:05

Spyros Kalams, MD

Vanderbilt University

What's Important from These Data & Where Do We Go from Here?

10:05 - 10:10

Troy Martin, MD, MPH

Fred Hutch

Questions & Answers

10:10 - 10:15

MORNING BREAK

10:15 - 10:45 AM

10:15 - 10:45 am Ambassador Ballroom

**BREAKOUT SESSIONS** 

10:15 - 10:45 AM

Microsoft Teams Refresher Drop-In

10:15 - 10:45 am Executive Room

Open Session chair: Mindy Miner

PLENARY 4 ● ★

10:45 AM - 12:45 PM

Combining T & B cell Immunity

10:45 am - 12:45 pm Regency Ballroom

Session chairs: Julie McElrath, MD, PhD/

Ryan Yucha, PhD

Fred Hutch/Seattle CAB Member

CD8 Correlates of Protection & Improving High-avidity T cell receptors

10:45 - 11:00

Mark Connors, MD

National Institutes of Health

TRM CD8 T cells – Role in Combined Immunity Protection & as Vaccine Targets

11:00 - 11:15

Vineet Joag, PhD

University of Minnesota

Correlates & Mechanisms of Combined T cell & B cell Immunity in the Mucosa – SHIV Challenge Model

11:15 - 11:30

Rama Amara, PhD

**Emory University** 

Considerations for Vaccine-mediated CD8+ T cell Responses in Lymphoid Tissues – Lessons from SIV Infected Rhesus Macaques

11:30 - 11:45

Michael Betts, PhD

University of Pennsylvania

T cell Vaccines in the Context of Human ATIs

11:45 - 12:00

Rachel Rutishauser, MD, PhD

University of California – San Francisco

Development of GrAd Highly Networked CD8+ T cell Epitope Vaccine for Human Clinical Trial

12:00 - 12:15

Ghurav Gaiha, MD, DPhil

Harvard University

Questions & Answers

12:15 - 12:45

TRANSLATIONAL ●★ SCIENCE AWARD

12:45 - 12:50 PM

12:45 – 2:50 pm Regency Ballroom

Session chair: Larry Corey, MD

Fred Hutch

KEY Plenary Open

Open Session Closed Session

Meals and Breaks

Live Streaming

🖈 Interpretation

LUNCH

12:45 - 2:00 PM

12:45 – 2:00 pm Ambassador Ballroom

**BREAKOUT SESSIONS** 

12:45 - 1:00 PM

Microsoft Teams Refresher Drop-In

12:45 – 1:00 pm Executive Room

Open Session chair: Mindy Miner

**BREAKOUT SESSIONS** 

1:00 - 1:30 PM

Lunch will be served in or near the meeting room

Protocol Chair & Co-Chair Interest Session

1:00 – 1:30 pm Congressional Room A&B

Open Session chairs: Carissa Carg & Alison Roxby

**BREAKOUT SESSIONS** 

1:00 - 2:00 PM

Lunch will be served in or near the meeting room

Breaking Down the Science Luncheon • \*

1:00 - 2:00 pm Empire Ballroom

Open Session Chair: Rafael Gonzalez

Road to Combo-AMP Update

1:00 – 2:00 pm Palladian Ballroom

Open Session chair: Huub Gelderblom

**HVTN 303 Writing Team Meeting** 

1:00 - 2:00 pm Executive Room

Open Session chair: Troy Martin

BREAKOUT SESSIONS 1:00 – 2:00 PM

Lunch will be served in or near the meeting room

Clinic Coordinator Breakout Session

1:00 – 2:00 pm Hampton Room

Closed Session chair: Brett Gray

**HVTN 300 Writing Team Meeting** 

1:00 - 2:00 pm Cabinet Room

Closed Session chair: Mindy Miner

BREAKOUT SESSIONS 1:30 – 2:00 PM

Lunch will be served in or near the meeting room

Scientific Leadership Development Program Overview

1:30 – 2:00 pm Congressional Room A&B

Open Session chair: Alison Roxby

2:00 - 2:20 pm Regency Ballroom

Session chair: Jim Kublin, MD, MPH

Fred Hutch

#### PLENARY 5 ● ★

2:20 - 5:00 PM

#### **RAMP Scholar Poster Discussion**

2:20 – 5:00 pm Regency Ballroom

Session chairs: Jim Kublin, MD, MPH/

Coco Alinsug

Fred Hutch/US GCAB Co-Chair

A Qualitative Study of MSM in NYC Diagnosed with MPOX: Examining the Impact of MPOX Stigma on Clinical Care

2:20 - 2:30

Devin Barzallo & Rachelle Monteau

Case Western Reserve University & CUNY School of Medicine

An Investigation on the Implications of Vaccine Induced Sero-Positivity (VISP) Post HIV Vaccine Efficacy Trial Participation in Zimbabwe

2:30 – 2:35 Tariq Mekkaoui Michigan State College

VOICES; Experiences and Perceptions About Accessing HIV Prevention and Participating in HIV Vaccine Trials- The Voices of Black Men Who Have Sex with Men (BMSM)

2:35 - 2:40

Chijoke Anyaehie, MBS Arkansas State University

Discovery of a SARS-CoV-2 RBD Specific Broadly Neutralizing Antibody

2:40 - 2:45

Ana Chang, PhD

Pacific Northwest University

Questions & Answers

2:45 - 3:05

Moderated by Jorge Sanchez, MD, CITBM

Unraveling VISP Comprehension: Exploring Insights in Cape Town, South Africa

3:05 – 3:10 Ruth St. Fort, MPH Wright State University

Evaluation of a Dual Point-of-Care Test for the Diagnosis of Syphilis in a High Prevalence HIV and STIs Setting

3:10 – 3:15 Efe Airwele

Northwestern University

Session Continued on Next Page...

#### PLENARY 5 ● ★

#### 2:20 - 5:00 PM

Influence of Medical Mistrust, Health Literacy, and Racism on Uptake of COVID-19 Vaccinations Among Men Who Have Sex with Men Living with HIV

3:15 - 3:20

Linh Le

California University of Science and Medicine

Sexual Health in Minoritized Communities Impacted by COVID-19 in New York City

3:20 - 3:25

Saba Ahmed

Pacific Northwest University

Examining the Attitudes and Beliefs of Black LGBTQ Individuals in Atlanta Towards COVID-19 Vaccines and HIV Vaccine Research

3:25 - 3:30

Samuel Owusu

Morehouse University

#### Questions & Answers

3:30 - 3:45

Moderated by Hong Van Tieu, MD, New York Blood Center

#### AFTERNOON BREAK

3:45 - 4:10 PM

3:45 - 4:10 pm

**Ambassador Ballroom** 

#### **BREAKOUT SESSIONS**

3:45 - 4:10 PM

#### Microsoft Teams Refresher Drop-In

3:45 - 4:10 pm

**Executive Room** 

Open Sessio

Session chair: Mindy Miner

#### PLENARY 5 • \*

2:20 - 5:00 PM

Barriers and Facilitators to Participation in HIV Research Studies Among Cisgender Women of Color

4:10 - 4:20

Shakira Laing & Corey Boltz

Erie Lake College & University of the Incarnate Word

Diagnosing Bacterial Vaginosis: A Comparison Between the Nugent Scoring System, Allplex™ Bacterial Vaginosis Assay and Point-of-Care BVBlue Test, South Africa

4:20 - 4:25

Simisola Tani-Olugbemi

Temple University

#### PLENARY 5 ● ★

#### 2:20 - 5:00 PM

Understanding Engagement to HIV Prevention and Sexual and Reproductive Health Services Among Women After Participating in an HIV Vaccine Trial

4:25 – 4:35 Ene Anteyi, MPH

Morehouse University

BE-XPLORE Study--Sexual Health Priorities Among Transgender and Gender Diverse People: A Mixed-Methods Analysis of Sexual Health and Safety in Relationships, HIV Risk Perception, and Barriers and Facilitators to Participation in HIV Prevention Research

4:35 – 4:40 Rosalind Byrd Emory University

Stick2PrEP Cisgender Women/Trans Individuals: Increasing Pre-Exposure Prophylaxis (PrEP) Uptake, Adherence, and Retention in Care, and Understanding PrEP Preferences Among Predominantly Black and Latinx Cisgender Women and Transgender Individuals

4:40 - 4:45

Jessika Carvalho Sanz, MD

**New York Institute** 

#### Questions & Answers

4:45 - 5:00

Moderated by Magda Sobieszczyk, MD, Columbia University

#### **BREAKOUT SESSION**

5:00 - 6:00 PM

## Sortase-conjugated CH505 Nanoparticle Vaccine Regimen

5:00 – 6:00 pm Executive Room

Closed Session chair: Troy Martin

#### HxB2 Writing Team Core Concept Call

5:00 – 6:00 pm Forum Room

Closed Session chair: Will Hahn

#### **BREAKOUT SESSION**

5:00 - 6:30 PM

#### HVTN Faith Initiative Fireside Chat ○ \*

5:00 - 6:30 pm Empire Ballroom

Open Session Chair: Ulysses Burley III

#### **BREAKOUT SESSIONS**

5:00 - 6:30 PM

#### **HVTN Lab Center Gathering**

5:00 - 6:30 pm

Birdcage Walk

Closed Session chair: Julie McElrath

## **HVTN/COVPN** POSTER SESSION

## RAMP SCHOLAR POSTER SESSION

Meet, mingle, and learn about innovative HIV & COVID-19 science being conducted by researchers, including the rising generation of researchers - our RAMP Scholars. Join us for a fun event to learn about their work.

#### Thursday, May 2<sup>ND</sup>

6:00 - 7:30 pm Regency Ballroom



#### PLENARY 6 ● ★

6:00 - 6:30 PM

#### Poster Session Flash Talks

All attendees should grab a headset before entering the ballroom

6:00 - 6:30 pm Regency Ballroom

Session chairs: Guido Ferrari, MD/Kyle Gordon Duke University/Fred Hutch

#### Method Development for Mucosal Antibody **Detection and Quantitation**

6:00 - 6:05 Caroline Brackett **Duke University** 

A Higher Proportion of Recent Compared to Historic HIV Viruses Are Resistant to Antibody Dependent Cellular Cytotoxicity Mediated by Monoclonal Antibodies

6:05 - 6:10 Dieter Mielke, PhD **Duke University** 

#### Transcrições: Art and Pedagogy in Promoting Equity in HIV Clinical Trials (Presented in Portuguese)

6:10 - 6:15Laylla Monteiro Instituto de Pesquisa Clinica Evandro Chagas

#### Non-Therapeutic Leukapheresis in the HVTN 305 HIV Vaccine Trial in South Africa

6:15 - 6:20

Nivashnee Naicker, MBChB

Centre for the AIDS Programme of Research in South Africa

#### Efficacy, Safety & Immunogenicity of H56:IC31 Vaccine for Prevention of Recurrent TB

6:20 - 6:25 Trevor Beattie The Aurum Institute

#### Questions & Answers

6:25 - 6:30

#### POSTER RECEPTION

6:30 - 7:30 PM

6:30 - 7:30 pm Regency Ballroom

Session chairs: Troy Martin, MD

HVTN researchers share posters. Please come to meet the presenters, while enjoying a glass of wine and a small bite.

#### **BREAKOUT SESSION**

6:30 - 7:30 PM

#### **HVTN Lab Center Leadership Group**

6:30 - 7:30 pm Congressional Room A&B Closed Session chair: Julie McElrath

#### **BREAKOUT SESSION**

6:30 - 7:30 PM

#### Community Engagement R01 Planning & Logistics (US Sites)

6:30 - 7:30 pm

Cabinet Room

Closed

Session chair: Michele Andrasik

#### HVTN 606 Site Meeting \*\*

6:30 - 7:30 pm

**Empire Ballroom** 

Closed

Session chair: Carrie Sopher

#### SGC DINNER

7:30 - 9:30 PM

7:30 - 9:30 pm

Palladian Ballroom

Closed

#### FRIDAY, MAY 3RD

#### Open Registration & Badge Pick-Up

7:00 am - 1:30 pm

West Registration Desk in the West Lobby (on the main floor of the hotel)

#### **BREAKFAST**

6:30 - 8:30 AM

6:30 - 8:30 am

Ambassador Ballroom

#### BREAKOUT SESSIONS

7:00 - 8:00 AM

Breakfast will be served in or near the meeting room

#### Community Wrap-Up Session • \*

7:00 - 8:00 am

**Empire Ballroom** 

Closed

Session chairs: Patricia Segura

#### **HVTN 807-ATI Site Meeting**

7:00 - 8:00 am

Palladian Ballroom

Closed

Session chairs: Manuel Villaran

#### PLENARY 7 ● ★

8:00 - 9:05 AM

#### Scientific Leadership Development Presentations

8:00 – 9:05 am

Regency Ballroom

Session chairs: Alison Roxby, MD, MSc/

Thoko Sifunda

Fred Hutch/International GCAB co-chair (Soweto-Bara CAB)

Pharmacokinetic Interaction Assessment of the HIV Broadly Neutralizing Monoclonal Antibody VRC07-523LS: A Cross-Protocol Analysis of Three Phase 1 HIV Prevention Trials HVTN127/HPTN087, HVTN130/HPTN089 and HVTN136/HPTN092

8.00 - 8.10

Tariro Chawana, MBChB, MSc

University of Zimbabwe, Seke South Clinical Research Site

#### PLENARY 7 ● ★

8:00 - 9:05 AM

Sex-specific Immune Responses to ALVAC-HIV and Bivalent Subtype C gp120/MF59 in the **HVTN 100 Clinical Trial in South Africa** 

8:10 - 8:20

Cassie Grimsley Ackerley, MD Hope Clinic, Emory University

Prevalence, Incidence and Predictors of Sexually Transmitted Infections and Associations with Baseline Immune Activation Among Women in the HVTN 705/HPX2008 Phase 2b HIV Vaccine Trial

8:20 - 8:30

Mitch Matoga, MBBS, MSc

University of North Carolina, Project Lilongwe

**HVTN 100 Part B Results: Safety and** immunogenicity of Month 30 boost of ALVAC + gp120/M59 preventive HIV vaccines

8:30 - 8:40

Vimla Naicker, MBChB

South African Medical Research Council

Time to Initiation of HIV Antiretroviral Therapy and Clinical Variables in Participants who acquire HIV: A Cross-Protocol Analysis of HVTN 703/HPTN 081 and HVTN 704/HPTN 085 Trials

8:40 - 8:50

Alfredo Jose Mena Lora

University of Illinois Chicago

#### Questions & Answers

8:50 - 9:05

#### **HIV VACCINE** TRIALS NETWORK WIZARD AWARD • \*

9:05 - 9:35 AM

9:05 - 9:35

Regency Ballroom Presented By: Larry Corey, MD

Larry Corey, MD, will present the "HIV Vaccine Trials Network Wizard Award" to Hugh Auchincloss, MD, retiring Deputy Director of NIAID, for his tireless support during and after the COVID-19 epidemic. In his absence, Jeanne Marrazzo, MD MPH, Director of NIAID, will accept the award and also give a presentation tentatively entitled "Update from the Director."

9:35 - 11:00 AM

#### Data Forum 2

9:35 – 11:00 am Regency Ballroom

Session chairs: Kelly Seaton, PhD/

Jarissa Greenard

Duke University/CER Working
Group Co-Chair (Vanderbilt CRS)

#### **HVTN 301 - Escalating Dose Priming**

9:35 - 9:55

Will Hahn, MD/Rachael Parks, PhD

Fred Hutch/Fred Hutch

## The HVTN 133 Story - Stopping for Safety, Evaluation of Putative Cause, & Reformulation of Product

9:55 - 10:10

Derek Cain, PhD

**Duke University** 

#### HVTN 302 - Safety Data, PEG Data, BAMA

10:10 - 10:25

Jesse Clark, MD, MSc

University of California Los Angeles

#### HVTN 305 - Safety Data, BC Phenotyping

10:25 - 10:40

Nivashnee Naicker, MBChB, MPH

Centre for the AIDS Programme of Research in South Africa

#### What Do These Data Mean for the HVTN?

10:40 - 10:50

Lindsey Baden, MD

Harvard University

#### Questions & Answers

10:50 - 11:00

#### **MORNING BREAK**

11:00 - 11:15 AM

11:00 - 11:15 am

Ambassador Ballroom

#### PLENARY 9 ● ★

11:15 AM - 12:30 PM

#### Meeting Wrap-Up

11:15 - 12:30 pm Regency Ballroom

Session chairs: Zoe Moodie, PhD/ Michele Andrasik, PhD Fred Hutch/Fred Hutch

#### Clinician Rapporteur

11:15 - 11:30

Preston Church, MD

Fred Hutch

#### Lab Rapporteur

11:30 - 11:45

Nathifa Moyo, PhD

Fred Hutch

#### Stats/Data Rapporteur

11:45 - 12:00

Shannon Grant, MS

Fred Hutch

#### Community Rapporteur

12:00 - 12:15

Derrick Mapp

Shanti Project

#### Closing Remarks

12:15 - 12:30

Larry Corey, MD

Fred Hutch

# **HVTN's 8th Translational HIV Vaccine Early-Stage Investigator Conference**

## October 21, 2024 The Westin New Orleans

The ESI Conference is intended for early-stage investigators who focus on translational HIV research in non-human primates (NHPs), or clinical HIV and TB research. Past attendees have stated that this conference has helped them increase their skills and knowledge for career development and provided them with a venue to form new collaborations.

#### Currently accepting Travel Award applications through May 15, 2024

To register for the conference and apply for a travel award, navigate to:

https://www.hvtn.org/events/hvtn-translational-hiv-vaccine-early-stage-investigator-esi-conference.html

A	
AAHI	Access to Advanced Health Institute
Ab	antibody
ACT-UP ACTG	AIDS Coalition to Unleash Power formerly AIDS Clinical Trials Group, now Advancing Clinical
ACIG	Therapeutics Globally
Ad	adenovirus (followed by a number indicating the strain/type)
ADA	anti-drug antibody
ADCC	antibody-dependent cellular cytotoxicity
ADCP	antibody-dependent cellular phagocytosis
AE	adverse event
AEC	absolute eosinophil count
AESI	adverse event of special interest
AF	aqueous formulation
AFAB	assigned female sex at birth
Ag	antigen
AHRI	Africa Health Research Institute
AIDS	acquired immunodeficiency syndrome
AIDSInfo	US Federal website for AIDS information
	(http://www.aidsinfo.nih.gov)
AIM assay	activation induced marker assay
ALT	alanine aminotransferase
Alum	aluminum hydroxide suspension
AMAB	assigned male sex at birth  American Foundation for AIDS Research
AmFAR AMP	antibody mediated prevention
ANOVA	analysis of variance
Anova	assessment of understanding
ART or AR	antiretroviral therapy
ASO	AIDS service organization
AST	aspartate aminotransferase
AUC or AUTC	area under the curve
ALICNAD	1 1 1 1 11
AUCMB	area under the magnitude breadth curve
AVAC	AIDS Vaccine Advocacy Coalition
	-
AVAC	AIDS Vaccine Advocacy Coalition
AVAC AVEG	AIDS Vaccine Advocacy Coalition AIDS Vaccine Evaluation Group (predecessor network to HVTN)
AVAC AVEG AVRS <b>B</b> β-HCG	AIDS Vaccine Advocacy Coalition AIDS Vaccine Evaluation Group (predecessor network to HVTN) AIDS Vaccine Research Subcommittee (NIAID) beta human chorionic gonadotropin
AVAC AVEG AVRS  B β-HCG B cell seq	AIDS Vaccine Advocacy Coalition AIDS Vaccine Evaluation Group (predecessor network to HVTN) AIDS Vaccine Research Subcommittee (NIAID) beta human chorionic gonadotropin B cell mRNA sequencing
AVAC AVEG AVRS  B β-HCG B cell seq BAMA	AIDS Vaccine Advocacy Coalition AIDS Vaccine Evaluation Group (predecessor network to HVTN) AIDS Vaccine Research Subcommittee (NIAID)  beta human chorionic gonadotropin B cell mRNA sequencing binding antibody multiplex assay
AVAC AVEG AVRS  B β-HCG B cell seq BAMA BCG	AIDS Vaccine Advocacy Coalition AIDS Vaccine Evaluation Group (predecessor network to HVTN) AIDS Vaccine Research Subcommittee (NIAID)  beta human chorionic gonadotropin B cell mRNA sequencing binding antibody multiplex assay bacille Calmette-Guérin (preventive TB vaccine)
AVAC AVEG AVRS  B β-HCG B cell seq BAMA BCG BCP	AIDS Vaccine Advocacy Coalition AIDS Vaccine Evaluation Group (predecessor network to HVTN) AIDS Vaccine Research Subcommittee (NIAID)  beta human chorionic gonadotropin B cell mRNA sequencing binding antibody multiplex assay bacille Calmette-Guérin (preventive TB vaccine) B-cell phenotyping
AVAC AVEG AVRS  B β-HCG B cell seq BAMA BCG BCP BCR	AIDS Vaccine Advocacy Coalition AIDS Vaccine Evaluation Group (predecessor network to HVTN) AIDS Vaccine Research Subcommittee (NIAID)  beta human chorionic gonadotropin B cell mRNA sequencing binding antibody multiplex assay bacille Calmette-Guérin (preventive TB vaccine) B-cell phenotyping B-cell receptor
AVAC AVEG AVRS  B β-HCG B cell seq BAMA BCG BCP BCR BIP	AIDS Vaccine Advocacy Coalition AIDS Vaccine Evaluation Group (predecessor network to HVTN) AIDS Vaccine Research Subcommittee (NIAID)  beta human chorionic gonadotropin B cell mRNA sequencing binding antibody multiplex assay bacille Calmette-Guérin (preventive TB vaccine) B-cell phenotyping B-cell receptor Baseline Immunogenicity Predictors
AVAC AVEG AVRS  B β-HCG B cell seq BAMA BCG BCP BCR BIP BLI	AIDS Vaccine Advocacy Coalition AIDS Vaccine Evaluation Group (predecessor network to HVTN) AIDS Vaccine Research Subcommittee (NIAID)  beta human chorionic gonadotropin B cell mRNA sequencing binding antibody multiplex assay bacille Calmette-Guérin (preventive TB vaccine) B-cell phenotyping B-cell receptor Baseline Immunogenicity Predictors BioLayer Interferometry
AVAC AVEG AVRS  B β-HCG B cell seq BAMA BCG BCP BCR BIP BLI BMGF	AIDS Vaccine Advocacy Coalition AIDS Vaccine Evaluation Group (predecessor network to HVTN) AIDS Vaccine Research Subcommittee (NIAID)  beta human chorionic gonadotropin B cell mRNA sequencing binding antibody multiplex assay bacille Calmette-Guérin (preventive TB vaccine) B-cell phenotyping B-cell receptor Baseline Immunogenicity Predictors BioLayer Interferometry Bill and Melinda Gates Foundation
AVAC AVEG AVRS  B β-HCG B cell seq BAMA BCG BCP BCR BIP BLI	AIDS Vaccine Advocacy Coalition AIDS Vaccine Evaluation Group (predecessor network to HVTN) AIDS Vaccine Research Subcommittee (NIAID)  beta human chorionic gonadotropin B cell mRNA sequencing binding antibody multiplex assay bacille Calmette-Guérin (preventive TB vaccine) B-cell phenotyping B-cell receptor Baseline Immunogenicity Predictors BioLayer Interferometry Bill and Melinda Gates Foundation body mass index
AVAC AVEG AVRS  B β-HCG B cell seq BAMA BCG BCP BCR BIP BLI BMGF BMI	AIDS Vaccine Advocacy Coalition AIDS Vaccine Evaluation Group (predecessor network to HVTN) AIDS Vaccine Research Subcommittee (NIAID)  beta human chorionic gonadotropin B cell mRNA sequencing binding antibody multiplex assay bacille Calmette-Guérin (preventive TB vaccine) B-cell phenotyping B-cell receptor Baseline Immunogenicity Predictors BioLayer Interferometry Bill and Melinda Gates Foundation
AVAC AVEG AVRS  B β-HCG B cell seq BAMA BCG BCP BCR BIP BLI BMGF BMI bnAb	AIDS Vaccine Advocacy Coalition AIDS Vaccine Evaluation Group (predecessor network to HVTN) AIDS Vaccine Research Subcommittee (NIAID)  beta human chorionic gonadotropin B cell mRNA sequencing binding antibody multiplex assay bacille Calmette-Guérin (preventive TB vaccine) B-cell phenotyping B-cell receptor Baseline Immunogenicity Predictors BioLayer Interferometry Bill and Melinda Gates Foundation body mass index broadly neutralizing antibody (capitalization may vary) blood pressure
AVAC AVEG AVRS  B β-HCG B cell seq BAMA BCG BCP BCR BIP BLI BMGF BMI bnAb BP	AIDS Vaccine Advocacy Coalition AIDS Vaccine Evaluation Group (predecessor network to HVTN) AIDS Vaccine Research Subcommittee (NIAID)  beta human chorionic gonadotropin B cell mRNA sequencing binding antibody multiplex assay bacille Calmette-Guérin (preventive TB vaccine) B-cell phenotyping B-cell receptor Baseline Immunogenicity Predictors BioLayer Interferometry Bill and Melinda Gates Foundation body mass index broadly neutralizing antibody (capitalization may vary)
AVAC AVEG AVRS  B β-HCG B cell seq BAMA BCG BCP BCR BIP BLI BMGF BMI bnAb BP BRR	AIDS Vaccine Advocacy Coalition AIDS Vaccine Evaluation Group (predecessor network to HVTN) AIDS Vaccine Research Subcommittee (NIAID)  beta human chorionic gonadotropin B cell mRNA sequencing binding antibody multiplex assay bacille Calmette-Guérin (preventive TB vaccine) B-cell phenotyping B-cell receptor Baseline Immunogenicity Predictors BioLayer Interferometry Bill and Melinda Gates Foundation body mass index broadly neutralizing antibody (capitalization may vary) blood pressure Bill of Rights and Responsibilities, for HIV or TB vaccine trials
AVAC AVEG AVRS  B β-HCG B cell seq BAMA BCG BCP BCR BIP BLI BMGF BMI bnAb BP BRR BSL	AIDS Vaccine Advocacy Coalition AIDS Vaccine Evaluation Group (predecessor network to HVTN) AIDS Vaccine Research Subcommittee (NIAID)  beta human chorionic gonadotropin B cell mRNA sequencing binding antibody multiplex assay bacille Calmette-Guérin (preventive TB vaccine) B-cell phenotyping B-cell receptor Baseline Immunogenicity Predictors BioLayer Interferometry Bill and Melinda Gates Foundation body mass index broadly neutralizing antibody (capitalization may vary) blood pressure Bill of Rights and Responsibilities, for HIV or TB vaccine trials
AVAC AVEG AVRS  B β-HCG B cell seq BAMA BCG BCP BCR BIP BLI BMGF BMI bnAb BP BRR BSL C	AIDS Vaccine Advocacy Coalition AIDS Vaccine Evaluation Group (predecessor network to HVTN) AIDS Vaccine Research Subcommittee (NIAID)  beta human chorionic gonadotropin B cell mRNA sequencing binding antibody multiplex assay bacille Calmette-Guérin (preventive TB vaccine) B-cell phenotyping B-cell receptor Baseline Immunogenicity Predictors BioLayer Interferometry Bill and Melinda Gates Foundation body mass index broadly neutralizing antibody (capitalization may vary) blood pressure Bill of Rights and Responsibilities, for HIV or TB vaccine trials biosafety level
AVAC AVEG AVRS  B β-HCG B cell seq BAMA BCG BCP BCR BIP BLI BMGF BMI bnAb BP BRR BSL C CAB/CAG	AIDS Vaccine Advocacy Coalition AIDS Vaccine Evaluation Group (predecessor network to HVTN) AIDS Vaccine Research Subcommittee (NIAID)  beta human chorionic gonadotropin B cell mRNA sequencing binding antibody multiplex assay bacille Calmette-Guérin (preventive TB vaccine) B-cell phenotyping B-cell receptor Baseline Immunogenicity Predictors BioLayer Interferometry Bill and Melinda Gates Foundation body mass index broadly neutralizing antibody (capitalization may vary) blood pressure Bill of Rights and Responsibilities, for HIV or TB vaccine trials biosafety level
AVAC AVEG AVRS  B β-HCG B cell seq BAMA BCG BCP BCR BIP BLI BMGF BMI bnAb BP BRR BSL C CAB/CAG CAPRISA	AIDS Vaccine Advocacy Coalition AIDS Vaccine Evaluation Group (predecessor network to HVTN) AIDS Vaccine Research Subcommittee (NIAID)  beta human chorionic gonadotropin B cell mRNA sequencing binding antibody multiplex assay bacille Calmette-Guérin (preventive TB vaccine) B-cell phenotyping B-cell receptor Baseline Immunogenicity Predictors BioLayer Interferometry Bill and Melinda Gates Foundation body mass index broadly neutralizing antibody (capitalization may vary) blood pressure Bill of Rights and Responsibilities, for HIV or TB vaccine trials biosafety level  community advisory board/group Centre for the AIDS Programme of Research in South Africa
AVAC AVEG AVRS  B β-HCG B cell seq BAMA BCG BCP BCR BIP BLI BMGF BMI bnAb BP BRR BSL C CAB/CAG CAPRISA CBC	AIDS Vaccine Advocacy Coalition AIDS Vaccine Evaluation Group (predecessor network to HVTN) AIDS Vaccine Research Subcommittee (NIAID)  beta human chorionic gonadotropin B cell mRNA sequencing binding antibody multiplex assay bacille Calmette-Guérin (preventive TB vaccine) B-cell phenotyping B-cell receptor Baseline Immunogenicity Predictors BioLayer Interferometry Bill and Melinda Gates Foundation body mass index broadly neutralizing antibody (capitalization may vary) blood pressure Bill of Rights and Responsibilities, for HIV or TB vaccine trials biosafety level  community advisory board/group Centre for the AIDS Programme of Research in South Africa complete blood count
AVAC AVEG AVRS  B β-HCG B cell seq BAMA BCG BCP BCR BIP BLI BMGF BMI bnAb BP BRR BSL C CAB/CAG CAPRISA CBC CBO CBPR CD4bs	AIDS Vaccine Advocacy Coalition AIDS Vaccine Evaluation Group (predecessor network to HVTN) AIDS Vaccine Research Subcommittee (NIAID)  beta human chorionic gonadotropin B cell mRNA sequencing binding antibody multiplex assay bacille Calmette-Guérin (preventive TB vaccine) B-cell phenotyping B-cell receptor Baseline Immunogenicity Predictors BioLayer Interferometry Bill and Melinda Gates Foundation body mass index broadly neutralizing antibody (capitalization may vary) blood pressure Bill of Rights and Responsibilities, for HIV or TB vaccine trials biosafety level  community advisory board/group Centre for the AIDS Programme of Research in South Africa complete blood count community-based organization community based participatory research CD4 binding site
AVAC AVEG AVEG AVRS  B β-HCG B cell seq BAMA BCG BCP BCR BIP BLI BMGF BMI bnAb BP BRR BSL C CAB/CAG CAPRISA CBC CBO CBPR CD4bs CDC	AIDS Vaccine Advocacy Coalition AIDS Vaccine Evaluation Group (predecessor network to HVTN) AIDS Vaccine Research Subcommittee (NIAID)  beta human chorionic gonadotropin B cell mRNA sequencing binding antibody multiplex assay bacille Calmette-Guérin (preventive TB vaccine) B-cell phenotyping B-cell receptor Baseline Immunogenicity Predictors BioLayer Interferometry Bill and Melinda Gates Foundation body mass index broadly neutralizing antibody (capitalization may vary) blood pressure Bill of Rights and Responsibilities, for HIV or TB vaccine trials biosafety level  community advisory board/group Centre for the AIDS Programme of Research in South Africa complete blood count community-based organization community based participatory research CD4 binding site Centers for Disease Control and Prevention (US)
AVAC AVEG AVRS  B β-HCG B cell seq BAMA BCG BCP BCR BIP BLI BMGF BMI bnAb BP BRR BSL C CAB/CAG CAPRISA CBC CBO CBPR CD4bs CDC CDM	AIDS Vaccine Advocacy Coalition AIDS Vaccine Evaluation Group (predecessor network to HVTN) AIDS Vaccine Research Subcommittee (NIAID)  beta human chorionic gonadotropin B cell mRNA sequencing binding antibody multiplex assay bacille Calmette-Guérin (preventive TB vaccine) B-cell phenotyping B-cell receptor Baseline Immunogenicity Predictors BioLayer Interferometry Bill and Melinda Gates Foundation body mass index broadly neutralizing antibody (capitalization may vary) blood pressure Bill of Rights and Responsibilities, for HIV or TB vaccine trials biosafety level  community advisory board/group Centre for the AIDS Programme of Research in South Africa complete blood count community-based organization community based participatory research CD4 binding site Centers for Disease Control and Prevention (US) Clinical Data Manager
AVAC AVEG AVRS  B β-HCG B cell seq BAMA BCG BCP BCR BIP BLI BMGF BMI bnAb BP BRR BSL C CAB/CAG CAPRISA CBC CBO CBPR CD4bs CDC CDM CE	AIDS Vaccine Advocacy Coalition AIDS Vaccine Evaluation Group (predecessor network to HVTN) AIDS Vaccine Research Subcommittee (NIAID)  beta human chorionic gonadotropin B cell mRNA sequencing binding antibody multiplex assay bacille Calmette-Guérin (preventive TB vaccine) B-cell phenotyping B-cell receptor Baseline Immunogenicity Predictors BioLayer Interferometry Bill and Melinda Gates Foundation body mass index broadly neutralizing antibody (capitalization may vary) blood pressure Bill of Rights and Responsibilities, for HIV or TB vaccine trials biosafety level  community advisory board/group Centre for the AIDS Programme of Research in South Africa complete blood count community-based organization community based participatory research CD4 binding site Centers for Disease Control and Prevention (US) Clinical Data Manager community engagement
AVAC AVEG AVRS  B β-HCG B cell seq BAMA BCG BCP BCR BIP BLI BMGF BMI bnAb BP BRR BSL C CAB/CAG CAPRISA CBC CBPR CD4bs CDC CDM CE CER	AIDS Vaccine Advocacy Coalition AIDS Vaccine Evaluation Group (predecessor network to HVTN) AIDS Vaccine Research Subcommittee (NIAID)  beta human chorionic gonadotropin B cell mRNA sequencing binding antibody multiplex assay bacille Calmette-Guérin (preventive TB vaccine) B-cell phenotyping B-cell receptor Baseline Immunogenicity Predictors BioLayer Interferometry Bill and Melinda Gates Foundation body mass index broadly neutralizing antibody (capitalization may vary) blood pressure Bill of Rights and Responsibilities, for HIV or TB vaccine trials biosafety level  community advisory board/group Centre for the AIDS Programme of Research in South Africa complete blood count community-based organization community based participatory research CD4 binding site Centers for Disease Control and Prevention (US) Clinical Data Manager community engagement Community Educator/Recruiter
AVAC AVEG AVRS  B β-HCG B cell seq BAMA BCG BCP BCR BIP BLI BMGF BMI bnAb BP BRR BSL C CAB/CAG CAPRISA CBC CBPR CD4bs CDC CDM CE CER CFAR	AIDS Vaccine Advocacy Coalition AIDS Vaccine Evaluation Group (predecessor network to HVTN) AIDS Vaccine Research Subcommittee (NIAID)  beta human chorionic gonadotropin B cell mRNA sequencing binding antibody multiplex assay bacille Calmette-Guérin (preventive TB vaccine) B-cell phenotyping B-cell receptor Baseline Immunogenicity Predictors BioLayer Interferometry Bill and Melinda Gates Foundation body mass index broadly neutralizing antibody (capitalization may vary) blood pressure Bill of Rights and Responsibilities, for HIV or TB vaccine trials biosafety level  community advisory board/group Centre for the AIDS Programme of Research in South Africa complete blood count community-based organization community based participatory research CD4 binding site Centers for Disease Control and Prevention (US) Clinical Data Manager community engagement Community Educator/Recruiter Center for AIDS Research
AVAC AVEG AVRS  B β-HCG B cell seq BAMA BCG BCP BCR BIP BLI BMGF BMI bnAb BP BRR BSL C CAB/CAG CAPRISA CBC CBC CCBC CDM CCE CER	AIDS Vaccine Advocacy Coalition AIDS Vaccine Evaluation Group (predecessor network to HVTN) AIDS Vaccine Research Subcommittee (NIAID)  beta human chorionic gonadotropin B cell mRNA sequencing binding antibody multiplex assay bacille Calmette-Guérin (preventive TB vaccine) B-cell phenotyping B-cell receptor Baseline Immunogenicity Predictors BioLayer Interferometry Bill and Melinda Gates Foundation body mass index broadly neutralizing antibody (capitalization may vary) blood pressure Bill of Rights and Responsibilities, for HIV or TB vaccine trials biosafety level  community advisory board/group Centre for the AIDS Programme of Research in South Africa complete blood count community-based organization community based participatory research CD4 binding site Centers for Disease Control and Prevention (US) Clinical Data Manager community engagement Community Educator/Recruiter

C	and a section of the
CFU	colony forming units
CGG	chronic granulomatous disease
CHAV	Consortium for HIV/AIDS Vaccine Development (Scripps)
CHAVI-ID	Center for HIV/AIDS Vaccine Immunology –
	Immunogen Discovery (NIAID)
CHIL	Cape Town HVTN Immunology Lab
СНО	Chinese hamster ovary
CI	confidence interval
CIOMS	Council for International Organizations of Medical Sciences
CMIA	chemiluminescent microparticle immunoassay
CMV	cytomegalovirus
COMPASS	combinatorial polyfunctionality analysis of
	antigen-specific T-cell subsets
CoP	correlate of protection
CoR	correlate of risk
CoVPN	COVID-19 Prevention Network
CP	Community Partners (a cross-network CAB convened by HANC)
CRAN	Comprehensive R Archive Network
CRF	case report form
CRMS	Clinical Research Management System (NIAID)
CRS	clinical research site
CRPMC	Clinical Research Products Management Center (NIAID)
Cryo-EM	cryogenic electron microscopy
CSF	cerebrospinal fluid
CSS	Clinical Safety Specialist
CSW	commercial sex worker
CTA	clinical trials agreement
CTL	cytotoxic T-lymphocyte
CTM	Clinical Trials Manager
CTU	clinical trials unit
D	
DAERS	DAIDS Adverse Experience Reporting System
DAIDS	Division of AIDS (at NIAID)
DHHS	· · ·
	Department of Health and Human Services (US)
DHVI	Duke Human Vaccine Institute
DTH	delayed-type hypersensitivity
DM	diabetes mellitus
DOV	discontinuation of vaccination
DS	disulfide
E	
EAE	expedited adverse event
EC	ethics committee
EC50	half-maximal effective concentration
eGFR	estimated glomerular filtration rate
EIA	enzyme immunoassay
ELISA	
22.071	enzyme-linked immunosorbent assay
ELISpot	enzyme-linked immunosorbent assay enzyme-linked immunosorbent spot
ELISpot	enzyme-linked immunosorbent spot electron microscopy
ELISpot EM EMPEM	enzyme-linked immunosorbent spot electron microscopy electron microscopy—based polyclonal epitome mapping
ELISpot EM EMPEM EMT	enzyme-linked immunosorbent spot electron microscopy electron microscopy—based polyclonal epitome mapping Executive Management Team (HVTN)
ELISpot EM EMPEM EMT	enzyme-linked immunosorbent spot electron microscopy electron microscopy—based polyclonal epitome mapping Executive Management Team (HVTN) envelope protein of HIV
ELISpot EM EMPEM EMT Env EQA	enzyme-linked immunosorbent spot electron microscopy electron microscopy—based polyclonal epitome mapping Executive Management Team (HVTN) envelope protein of HIV external quality assurance
ELISpot EM EMPEM EMT Env EQA EQAPOL	enzyme-linked immunosorbent spot electron microscopy electron microscopy—based polyclonal epitome mapping Executive Management Team (HVTN) envelope protein of HIV external quality assurance external quality assurance program oversight laboratory
ELISpot EM EMPEM EMT Env EQA EQAPOL ETWG	enzyme-linked immunosorbent spot electron microscopy electron microscopy—based polyclonal epitome mapping Executive Management Team (HVTN) envelope protein of HIV external quality assurance external quality assurance program oversight laboratory Efficacy Trials Working Group (HVTN)
ELISpot EM EMPEM EMT Env EQA EQAPOL	enzyme-linked immunosorbent spot electron microscopy electron microscopy—based polyclonal epitome mapping Executive Management Team (HVTN) envelope protein of HIV external quality assurance external quality assurance program oversight laboratory
ELISpot EM EMPEM EMT Env EQA EQAPOL ETWG	enzyme-linked immunosorbent spot electron microscopy electron microscopy—based polyclonal epitome mapping Executive Management Team (HVTN) envelope protein of HIV external quality assurance external quality assurance program oversight laboratory Efficacy Trials Working Group (HVTN)
ELISpot EM EMPEM EMT Env EQA EQAPOL ETWG EUA	enzyme-linked immunosorbent spot electron microscopy electron microscopy—based polyclonal epitome mapping Executive Management Team (HVTN) envelope protein of HIV external quality assurance external quality assurance program oversight laboratory Efficacy Trials Working Group (HVTN) Emergency Use Authorization
ELISpot EM EMPEM EMT Env EQA EQAPOL ETWG EUA EUL	enzyme-linked immunosorbent spot electron microscopy electron microscopy—based polyclonal epitome mapping Executive Management Team (HVTN) envelope protein of HIV external quality assurance external quality assurance program oversight laboratory Efficacy Trials Working Group (HVTN) Emergency Use Authorization emergency use listing
ELISpot EM EMPEM EMT Env EQA EQAPOL ETWG EUA EUL EUROVACC	enzyme-linked immunosorbent spot electron microscopy electron microscopy—based polyclonal epitome mapping Executive Management Team (HVTN) envelope protein of HIV external quality assurance external quality assurance program oversight laboratory Efficacy Trials Working Group (HVTN) Emergency Use Authorization emergency use listing
ELISpot EM EMPEM EMT Env EQA EQAPOL ETWG EUA EUL EUROVACC F FBO	enzyme-linked immunosorbent spot electron microscopy electron microscopy—based polyclonal epitome mapping Executive Management Team (HVTN) envelope protein of HIV external quality assurance external quality assurance program oversight laboratory Efficacy Trials Working Group (HVTN) Emergency Use Authorization emergency use listing European Vaccine Effort Against HIV/AIDS
ELISpot EM EMPEM EMT Env EQA EQAPOL ETWG EUA EUL EUROVACC F FBO FCR	enzyme-linked immunosorbent spot electron microscopy electron microscopy—based polyclonal epitome mapping Executive Management Team (HVTN) envelope protein of HIV external quality assurance external quality assurance program oversight laboratory Efficacy Trials Working Group (HVTN) Emergency Use Authorization emergency use listing European Vaccine Effort Against HIV/AIDS  faith-based organization Fc- receptors
ELISpot EM EMPEM EMT Env EQA EQAPOL ETWG EUA EUL EUROVACC F FBO FCR FDA	enzyme-linked immunosorbent spot electron microscopy electron microscopy—based polyclonal epitome mapping Executive Management Team (HVTN) envelope protein of HIV external quality assurance external quality assurance program oversight laboratory Efficacy Trials Working Group (HVTN) Emergency Use Authorization emergency use listing European Vaccine Effort Against HIV/AIDS  faith-based organization Fc- receptors Food and Drug Administration (US)
ELISpot EM EMPEM EMT Env EQA EQAPOL ETWG EUA EUL EUROVACC F FBO FcR FDA FHCC	enzyme-linked immunosorbent spot electron microscopy electron microscopy—based polyclonal epitome mapping Executive Management Team (HVTN) envelope protein of HIV external quality assurance external quality assurance program oversight laboratory Efficacy Trials Working Group (HVTN) Emergency Use Authorization emergency use listing European Vaccine Effort Against HIV/AIDS  faith-based organization Fc- receptors Food and Drug Administration (US) Fred Hutchinson Cancer Center, or Fred Hutch
ELISpot EM EMPEM EMT Env EQA EQAPOL ETWG EUA EUL EUROVACC F FBO FCR FDA	enzyme-linked immunosorbent spot electron microscopy electron microscopy—based polyclonal epitome mapping Executive Management Team (HVTN) envelope protein of HIV external quality assurance external quality assurance program oversight laboratory Efficacy Trials Working Group (HVTN) Emergency Use Authorization emergency use listing European Vaccine Effort Against HIV/AIDS  faith-based organization Fc- receptors Food and Drug Administration (US)

F		L	
FPR	false positive rate	LABA	long-acting beta agonist
FS	functionality score	LAM	lipoarabinomannan
G		LC	Laboratory Center (of the HVTN)
GC	germinal center	LOC	Leadership and Operations Center (of the HVTN)
GCP	Good Clinical Practice	LS	an antibody half-life extension mutation on the
GCLP	Good Clinical Laboratory Practice		Fc region of an antibody
GEE	generalized estimating equation	LTFU	lost to follow-up OR long term follow-up
GINA	Genetic Information Nondiscrimination Act	M	
GMP	Good Manufacturing Practice	MAAE	medically attended adverse event
GPP	Good Participatory Practice	mAb	monoclonal antibody
Н		MAR	missing at random
HANC	Office of HIV/AIDS Network Coordination	MCAR	missing completely at random
	(NIAID, located at Fred Hutch)	MCC	Medicines Control Council (South Africa)
HBsAg	hepatitis B surface antigen	Mcg	microgram
HCRISA	Hutchinson Centre Research Institute of South Africa	MedDRA	Medical Dictionary for Regulatory Activities
HCV	hepatitis C virus	MFI	mean fluorescence intensity
Hgb	hemoglobin	MHC	major histocompatibility complex
HHS	Department of Health and Human Services (US)	MIF	
			macrophage migration inhibitory factor
HIPAA	Health Insurance Portability and Accountability Act (US)	MIMOSA	mixture models for single-cell assays
HIVNET	HIV Network for Prevention Trials (NIAID, closed October 1999)	MLV	murine leukemia virus
HIT	heparin-induced thrombocytopenia	MMR	measles, mumps, and rubella vaccine
HIV	human immunodeficiency virus	MO	Medical Officer (DAIDS)
HLA	human leukocyte antigen	MOP	Manual of Operations Procedures
HPTN	HIV Prevention Trials Network	MPER	membrane proximal external region
HSV2	herpes simplex virus type 2	MRC	Medical Research Council (South Africa)
HVTN	HIV Vaccine Trials Network	MSD	Meso Scale Discovery assay
I		MSM	men who have sex with men
IAS-USA	International Antiviral Society – USA	M.tb	Mycobacterium tuberculosis
IAVI	International AIDS Vaccine Initiative	MTBC	M. tuberculosis complex
IB	Investigator's Brochure	MVA	modified Ankara virus
IBC	Institutional Biosafety Committee	N	
IC50	inhibitory concentration of 50% (median)	nAb	neutralizing antibody
IC80	inhibitory concentration of 80%	nnAb	non-neutralizing antibody
ICABA	infected cells antibody binding assay	NAT	nucleic acid test
ICH	International Council for Harmonisation of Technical	NB	non-binary
	Requirements for Pharmaceuticals for Human Use	NEC	Network Evaluation Committee (HVTN)
ICS	intracellular cytokine staining assay	NFL	native flexibly linked
ID	intradermal	NGO	non-governmental organization
ID50	50% inhibitory dose (median)	NHP	nonhuman primate
ID80	80% inhibitory dose	NK	natural killer cells
IFN-γ	interferon-gamma	NIAID	National Institute of Allergy and Infectious Diseases
lg .	immunoglobulin		(of the US NIH)
IgA	immunoglobulin A	NICD	National Institute for Communicable Diseases (South Africa)
IgG	immunoglobulin G	NIH	National Institutes of Health
IgM	immunoglobulin M	NLT	native-like HIV Env trimer
IGRA	interferon-gamma release assay	NSAID	nonsteroidal anti-inflammatory drug
IL	interleukin	0	nonsteroladi ditti ililidililildeory di dg
IM	intramuscular	OAR	Office of AIDS Research (NIH)
IMPAACT	International Maternal Pediatric Adolescent AIDS Clinical Trials	OARAC	Office of AIDS Research Advisory Committee (NIH)
IN	intranasal	OBA	Office of Biotechnology Activities (NIH)
IND	Investigational New Drug (application to FDA)	OCGR	Office of Communications and Government Relations (NIAID)
INH	isoniazid	OHRP	Office for Human Research Protections (at the NIH)
INR	international normalized ratio	OPCRO	Office for Policy in Clinical Research Operations (NIAID)
IOR	Investigator of Record	OPV	oral polio vaccine
IRAMP	International Research and Mentorship Program (HVTN)	P	Discourse that Affaire Day of (All Affa)
IRB	Institutional Review Board	PAB	Pharmaceutical Affairs Branch (NIAID)
IRM	immune response modifier	PBMC	peripheral blood mononuclear cell
ITT	intent-to-treat	PBS	phosphate-buffered saline
IUD	intrauterine device	PCA	principal component analysis
		PCR	polymerase chain reaction
IV	intravenous		
IV K	intravenous	PD	pharmacodynamics
	intravenous knock-in		
K		PD	pharmacodynamics

P	
PK	pharmacokinetics
PM	Project Manager
PE	prevention efficacy
PEF	peak expiratory flow
PEP	post-exposure prophylaxis
PFS	polyfunctionality score
PHRU	Perinatal HIV Research Unit (site in Soweto)
PI	Principal Investigator
PID	pelvic inflammatory disease
PIMMC	potential immune-mediated medical condition
Pol	polymerase (generally of HIV)
PrEP	pre-exposure prophylaxis
PSRT	Protocol Safety Review Team
PT	preferred term OR protocol team
PT50	predicted serum neutralization 50% inhibitory dilution titer biomarker (ID50)
PT80	predicted serum neutralization 80% inhibitory dilution titer
	biomarker (ID80)
PTL	Protocol Team Leader
PWH	people with HIV
PLWH	people living with HIV
POD	prevention of disease
POPIA	Protection of Personal Information Act (South Africa)
PPD	purified protein derivative; also the name of
	DAIDS' contracted study monitoring agency
PSRC	Prevention Science Review Committee (DAIDS)
PSRT	Protocol Safety Review Team
PTE	potential T-cell epitope
Q	potential 1-cen epitope
QADVIP	Quality Assurance for Duke Vaccine Immunogenicity Programs
QAU	Quality Assurance Unit
QFT	Quantiferon tuberculosis
•	Quantiferon tuberculosis
aDCD	quantitative polymerase chain reaction
qPCR	quantitative polymerase chain reaction
R	
R RA	regulatory authority
R RA RAB	regulatory authority Regulatory Affairs Branch (NIAID)
R RA RAB RAMP	regulatory authority Regulatory Affairs Branch (NIAID) Research and Mentorship Program (HVTN)
R RA RAB RAMP RBD	regulatory authority Regulatory Affairs Branch (NIAID) Research and Mentorship Program (HVTN) receptor binding domain
R RA RAB RAMP RBD RCT	regulatory authority Regulatory Affairs Branch (NIAID) Research and Mentorship Program (HVTN) receptor binding domain randomized controlled trial
R RA RAB RAMP RBD RCT RE	regulatory authority Regulatory Affairs Branch (NIAID) Research and Mentorship Program (HVTN) receptor binding domain randomized controlled trial regulatory entity
R RA RAB RAMP RBD RCT RE REDCap	regulatory authority Regulatory Affairs Branch (NIAID) Research and Mentorship Program (HVTN) receptor binding domain randomized controlled trial regulatory entity Research Electronic Data Capture
R RA RAB RAMP RBD RCT RE REDCap RhCMV	regulatory authority Regulatory Affairs Branch (NIAID) Research and Mentorship Program (HVTN) receptor binding domain randomized controlled trial regulatory entity Research Electronic Data Capture rhesus cytomegalovirus
R RA RAB RAMP RBD RCT RE REDCap RhCMV RML	regulatory authority Regulatory Affairs Branch (NIAID) Research and Mentorship Program (HVTN) receptor binding domain randomized controlled trial regulatory entity Research Electronic Data Capture rhesus cytomegalovirus Regional Medical Liaison
R RA RAB RAMP RBD RCT RE REDCap RhCMV RML RNA-Seq	regulatory authority Regulatory Affairs Branch (NIAID) Research and Mentorship Program (HVTN) receptor binding domain randomized controlled trial regulatory entity Research Electronic Data Capture rhesus cytomegalovirus Regional Medical Liaison RNA sequencing
R RA RAB RAMP RBD RCT RE REDCap RhCMV RML RNA-Seq RSC	regulatory authority Regulatory Affairs Branch (NIAID) Research and Mentorship Program (HVTN) receptor binding domain randomized controlled trial regulatory entity Research Electronic Data Capture rhesus cytomegalovirus Regional Medical Liaison
R RA RAB RAMP RBD RCT RE REDCap RhCMV RML RNA-Seq RSC S	regulatory authority Regulatory Affairs Branch (NIAID) Research and Mentorship Program (HVTN) receptor binding domain randomized controlled trial regulatory entity Research Electronic Data Capture rhesus cytomegalovirus Regional Medical Liaison RNA sequencing Regulatory Support Center at DAIDS
R RA RAB RAMP RBD RCT RE REDCap RhCMV RML RNA-Seq RSC S SA	regulatory authority Regulatory Affairs Branch (NIAID) Research and Mentorship Program (HVTN) receptor binding domain randomized controlled trial regulatory entity Research Electronic Data Capture rhesus cytomegalovirus Regional Medical Liaison RNA sequencing Regulatory Support Center at DAIDS
R RA RAB RAMP RBD RCT RE REDCap RhCMV RML RNA-Seq RSC S SA SAAVI	regulatory authority Regulatory Affairs Branch (NIAID) Research and Mentorship Program (HVTN) receptor binding domain randomized controlled trial regulatory entity Research Electronic Data Capture rhesus cytomegalovirus Regional Medical Liaison RNA sequencing Regulatory Support Center at DAIDS  specific activity South African AIDS Vaccine Initiative
R RA RAB RAMP RBD RCT RE REDCap RhCMV RML RNA-Seq RSC S SA SAAVI SAE	regulatory authority Regulatory Affairs Branch (NIAID) Research and Mentorship Program (HVTN) receptor binding domain randomized controlled trial regulatory entity Research Electronic Data Capture rhesus cytomegalovirus Regional Medical Liaison RNA sequencing Regulatory Support Center at DAIDS  specific activity South African AIDS Vaccine Initiative serious adverse event
R RA RAB RAMP RBD RCT RE REDCap RhCMV RML RNA-Seq RSC S SA SAAVI SAE SAHPRA	regulatory authority Regulatory Affairs Branch (NIAID) Research and Mentorship Program (HVTN) receptor binding domain randomized controlled trial regulatory entity Research Electronic Data Capture rhesus cytomegalovirus Regional Medical Liaison RNA sequencing Regulatory Support Center at DAIDS  specific activity South African AIDS Vaccine Initiative serious adverse event South African Health Products Regulatory Authority
R RA RAB RAMP RBD RCT RE REDCap RhCMV RML RNA-Seq RSC S SA SAAVI SAE SAHPRA SAP	regulatory authority Regulatory Affairs Branch (NIAID) Research and Mentorship Program (HVTN) receptor binding domain randomized controlled trial regulatory entity Research Electronic Data Capture rhesus cytomegalovirus Regional Medical Liaison RNA sequencing Regulatory Support Center at DAIDS  specific activity South African AIDS Vaccine Initiative serious adverse event South African Health Products Regulatory Authority statistical analysis plan
R RA RAB RAMP RBD RCT RE REDCap RhCMV RML RNA-Seq RSC S SA SAAVI SAE SAHPRA SAP SAS	regulatory authority Regulatory Affairs Branch (NIAID) Research and Mentorship Program (HVTN) receptor binding domain randomized controlled trial regulatory entity Research Electronic Data Capture rhesus cytomegalovirus Regional Medical Liaison RNA sequencing Regulatory Support Center at DAIDS  specific activity South African AIDS Vaccine Initiative serious adverse event South African Health Products Regulatory Authority statistical analysis plan statistical analysis system
R RA RAB RAMP RBD RCT RE REDCap RhCMV RML RNA-Seq RSC S SA SAAVI SAE SAHPRA SAP SAS SATVI	regulatory authority Regulatory Affairs Branch (NIAID) Research and Mentorship Program (HVTN) receptor binding domain randomized controlled trial regulatory entity Research Electronic Data Capture rhesus cytomegalovirus Regional Medical Liaison RNA sequencing Regulatory Support Center at DAIDS  specific activity South African AIDS Vaccine Initiative serious adverse event South African Health Products Regulatory Authority statistical analysis plan statistical analysis system South African TB Vaccine Initiative
R RA RAB RAMP RBD RCT RE REDCap RhCMV RML RNA-Seq RSC S SA SAAVI SAE SAHPRA SAP SAS SATVI SBS	regulatory authority Regulatory Affairs Branch (NIAID) Research and Mentorship Program (HVTN) receptor binding domain randomized controlled trial regulatory entity Research Electronic Data Capture rhesus cytomegalovirus Regional Medical Liaison RNA sequencing Regulatory Support Center at DAIDS  specific activity South African AIDS Vaccine Initiative serious adverse event South African Health Products Regulatory Authority statistical analysis plan statistical analysis system South African TB Vaccine Initiative social and behavioral sciences
R RA RAB RAMP RBD RCT RE REDCap RhCMV RML RNA-Seq RSC S SA SAAVI SAE SAHPRA SAP SAS SATVI	regulatory authority Regulatory Affairs Branch (NIAID) Research and Mentorship Program (HVTN) receptor binding domain randomized controlled trial regulatory entity Research Electronic Data Capture rhesus cytomegalovirus Regional Medical Liaison RNA sequencing Regulatory Support Center at DAIDS  specific activity South African AIDS Vaccine Initiative serious adverse event South African Health Products Regulatory Authority statistical analysis plan statistical analysis system South African TB Vaccine Initiative social and behavioral sciences Social & Behavioral Sciences and Community Engagement Unit (HVTN)
R RA RAB RAMP RBD RCT RE REDCap RhCMV RML RNA-Seq RSC S SA SAAVI SAE SAHPRA SAP SAS SATVI SBS	regulatory authority Regulatory Affairs Branch (NIAID) Research and Mentorship Program (HVTN) receptor binding domain randomized controlled trial regulatory entity Research Electronic Data Capture rhesus cytomegalovirus Regional Medical Liaison RNA sequencing Regulatory Support Center at DAIDS  specific activity South African AIDS Vaccine Initiative serious adverse event South African Health Products Regulatory Authority statistical analysis plan statistical analysis system South African TB Vaccine Initiative social and behavioral sciences Social & Behavioral Sciences and Community
R RA RAB RAMP RBD RCT RE REDCap RhCMV RML RNA-Seq RSC S SA SAAVI SAE SAHPRA SAP SAS SATVI SBS SBS-CEU	regulatory authority Regulatory Affairs Branch (NIAID) Research and Mentorship Program (HVTN) receptor binding domain randomized controlled trial regulatory entity Research Electronic Data Capture rhesus cytomegalovirus Regional Medical Liaison RNA sequencing Regulatory Support Center at DAIDS  specific activity South African AIDS Vaccine Initiative serious adverse event South African Health Products Regulatory Authority statistical analysis plan statistical analysis system South African TB Vaccine Initiative social and behavioral sciences Social & Behavioral Sciences and Community Engagement Unit (HVTN)
R RA RAB RAMP RBD RCT RE REDCap RhCMV RML RNA-Seq RSC S SA SAAVI SAE SAHPRA SAP SAS SATVI SBS SBS-CEU	regulatory authority Regulatory Affairs Branch (NIAID) Research and Mentorship Program (HVTN) receptor binding domain randomized controlled trial regulatory entity Research Electronic Data Capture rhesus cytomegalovirus Regional Medical Liaison RNA sequencing Regulatory Support Center at DAIDS  specific activity South African AIDS Vaccine Initiative serious adverse event South African Health Products Regulatory Authority statistical analysis plan statistical analysis system South African TB Vaccine Initiative social and behavioral sciences Social & Behavioral Sciences and Community Engagement Unit (HVTN) Social and Behavioral Sciences Working Group (HVTN) subcutaneous Statistical Center for HIV/AIDS Research and Prevention
R RA RAB RAMP RBD RCT RE REDCap RhCMV RML RNA-Seq RSC S SA SAAVI SAE SAHPRA SAP SAS SATVI SBS SBS-CEU SBWG SC	regulatory authority Regulatory Affairs Branch (NIAID) Research and Mentorship Program (HVTN) receptor binding domain randomized controlled trial regulatory entity Research Electronic Data Capture rhesus cytomegalovirus Regional Medical Liaison RNA sequencing Regulatory Support Center at DAIDS  specific activity South African AIDS Vaccine Initiative serious adverse event South African Health Products Regulatory Authority statistical analysis plan statistical analysis system South African TB Vaccine Initiative social and behavioral sciences Social & Behavioral Sciences and Community Engagement Unit (HVTN) Social and Behavioral Sciences Working Group (HVTN) subcutaneous
R RA RAB RAMP RBD RCT RE REDCap RhCMV RML RNA-Seq RSC S SA SAAVI SAE SAHPRA SAP SAS SATVI SBS SBS-CEU SBWG SC SCHARP	regulatory authority Regulatory Affairs Branch (NIAID) Research and Mentorship Program (HVTN) receptor binding domain randomized controlled trial regulatory entity Research Electronic Data Capture rhesus cytomegalovirus Regional Medical Liaison RNA sequencing Regulatory Support Center at DAIDS  specific activity South African AIDS Vaccine Initiative serious adverse event South African Health Products Regulatory Authority statistical analysis plan statistical analysis system South African TB Vaccine Initiative social and behavioral sciences Social & Behavioral Sciences and Community Engagement Unit (HVTN) Social and Behavioral Sciences Working Group (HVTN) subcutaneous Statistical Center for HIV/AIDS Research and Prevention (serves as HVTN's SDMC) severe combined immunodeficient
R RA RAB RAMP RBD RCT RE REDCap RhCMV RML RNA-Seq RSC S SA SAAVI SAE SAHPRA SAP SAS SATVI SBS SBS-CEU SBWG SC SCHARP SCID SCORE	regulatory authority Regulatory Affairs Branch (NIAID) Research and Mentorship Program (HVTN) receptor binding domain randomized controlled trial regulatory entity Research Electronic Data Capture rhesus cytomegalovirus Regional Medical Liaison RNA sequencing Regulatory Support Center at DAIDS  specific activity South African AIDS Vaccine Initiative serious adverse event South African Health Products Regulatory Authority statistical analysis plan statistical analysis system South African TB Vaccine Initiative social and behavioral sciences Social & Behavioral Sciences and Community Engagement Unit (HVTN) Social and Behavioral Sciences Working Group (HVTN) subcutaneous Statistical Center for HIV/AIDS Research and Prevention (serves as HVTN's SDMC)
R RA RAB RAMP RBD RCT RE REDCap RhCMV RML RNA-Seq RSC S SA SAAVI SAE SAHPRA SAP SAS SATVI SBS SBS-CEU SBWG SC SCHARP	regulatory authority Regulatory Affairs Branch (NIAID) Research and Mentorship Program (HVTN) receptor binding domain randomized controlled trial regulatory entity Research Electronic Data Capture rhesus cytomegalovirus Regional Medical Liaison RNA sequencing Regulatory Support Center at DAIDS  specific activity South African AIDS Vaccine Initiative serious adverse event South African Health Products Regulatory Authority statistical analysis plan statistical analysis system South African TB Vaccine Initiative social and behavioral sciences Social & Behavioral Sciences and Community Engagement Unit (HVTN) Social and Behavioral Sciences Working Group (HVTN) subcutaneous Statistical Center for HIV/AIDS Research and Prevention (serves as HVTN's SDMC) severe combined immunodeficient Site Clinical Operations and Research Essentials (manual)

S	
SEG	Special Emphasis Group (Laboratory)
SFC	spot-forming cell
SFU	spot-forming unit
SGC	Scientific Governance Committee (HVTN)
SHD	standard human dose
SHIV	simian-human immunodeficiency virus
SICF	sample informed consent form
slgA	secretory IgA
SIV	simian immunodeficiency virus
SLD	Scientific Leadership Development program (HVTN)
SMB	Safety Monitoring Board
SMQ	Standard MedDRA Query
SOP	•
SPT	standard operating procedures
	Safety and Pharmacovigilance Team (DAIDS)
SRC	Scientific Review Committee (HVTN)
SSP	study-specific procedures
STI/D	sexually transmitted infection/disease
SUDL	Specimen Use Decision Log
SUSAR	suspected unexpected serious adverse reaction
Т	
TAG	Treatment Action Group
ТВ	tuberculosis
TBVI	Tuberculosis Vaccine Initiative
TCID50	median tissue culture infectious dose
TEAE	treatment emergent adverse event
TG	transgender, also "trans"
TGNB	transgender and non-binary
TLR	toll-like receptor
TMLE	targeted minimum loss-based estimation
TPT	tuberculosis preventive treatment
TST	tuberculin skin test
TT	tetanus toxoid
TTS	thrombosis with thrombocytopenia syndrome
U	thrombosis with thrombocytopenia syndrome
	micro
μ	
μg	microgram
ULN/ULQ	upper limit of normal/upper limit of quantitation
UNAIDS	Joint United Nations Programme on HIV/AIDS
USAID	United States Agency for International Development
USMHRP	US Military HIV Research Program
USP	United States Pharmacopeia
UW-VSL	University of Washington Virology Specialty Laboratory
V	
VAERS	Vaccine Adverse Event Reporting System (through CDC)
VAX300	VaxINator Intranasal Atomization Device
VISC	Vaccine Immunology Statistical Center
VISP/r	vaccine-induced seropositivity/seroreactivity
VL	viral load
VP	viral particle
VRC	Dale and Betty Bumpers Vaccine Research Center (at NIAID)
W	
WBC	white blood cell
WCL	whole cell lysate (of TB)
WG	working group
WHO	World Health Organization
WRAIR	Walter Reed Army Institute of Research
WT	wild-type
	- 71-7

## TUESDAY, APRIL 30TH

TIME	REGENCY BALLROOM	EMPIRE BALLROOM	PALLADIAN BALLROOM	HAMPTON ROOM	EXECUTIVE ROOM
6:30					
7:00					
7:30					
8:00					
8:30					
9:00					
9:30					
10:00					
10:30					
11:00					
11:30					
12:00					
12:30					
1:00					
1:30					
2:00					
2:30					
3:00					
3:30					
4:00					
4:30					
5:00					
5:30					
6:00					
6:30					
7:00					
7:30					
8:00					
8:30					
9:00					
9:30					

CONGRESSIONAL ROOM A & B	CABINET ROOM	FORUM ROOM	AMBASSADOR BALLROOM	BIRDCAGE WALK	WEST REGISTRATION DESK	TIME
						6:30
						7:00
						7:30
						8:00
						8:30
						9:00
						9:30
						10:00
						10:30
						11:00
						11:30
						12:00
						12:30
						1:00
						1:30
						2:00
						2:30
						3:00
						3:30
						4:00
						4:30
						5:00
						5:30
						6:00
					Open Registration & Badge Pick-Up	6:30
					(6:00 – 8:00 pm)	7:00
						7:30
						8:00
						8:30
						9:00
						9:30

KEY

Open Session

Closed Session


Meals and Breaks

Live Streaming

\* Interpretation

## WEDNESDAY, MAY 1ST -

TIME	REGENCY BALLROOM	EMPIRE BALLROOM	PALLADIAN BALLROOM	HAMPTON ROOM	EXECUTIVE ROOM
6:30					
7:00		<b>○</b> *			
7:30		HVTN for First Timers (7:15 - 8:15 am)	HVTN 142/VIR 1388_ V01 Site Meeting (7:15 - 8:15 am)		Efficacy Trials Working Group (7:15 - 8:15 am)
8:00	• * Non-Technical Day 1 (8:15 - 8:30 am)		(7.13 G.13 dill)		(7.13 0.13 dill)
8:30	• <b>*</b> Plenary 1:				
9:00	Road to Combo-AMP				
9:30	(8:30 - 10:30 am)				
10:00					
10:30					
11:00	• * Plenary 2: The Impact of bnAbs on Our Future?				
11:30	(11:00 - 12:30 pm)				
12:00					
12:30					
1:00		○ ★ Breaking Down the			NEC Meeting
1:30		Science Luncheon (1:00 - 2:00 pm)			(1:00 - 2:00 pm)
2:00		● ★ General Community Session	Investigators		HVTN Lab Center Team Review
2:30	Investigators Meet the Professors Seminar:	(2:00 - 3:00 pm)	Meet the Professors		(2:00 - 3:00 pm)
3:00	(2:00 – 4:00 pm)	● ★ CAB Breakout Session	Seminar:		
3:30		(3:00 - 4:00 pm)	(2:00 – 4:00 pm)		
4:00		Community Stakeholder Conversation:			
4:30		bnAbs & Way Forward (4:00 - 5:00 pm)	HVTN 313 Site Meeting		HVTN 141/HPTN 105 Protocol
5:00		Research & Mentorship	(4:30 - 5:30 pm)		Team Meeting (4:30 - 5:30 pm)
5:30		Program (RAMP)  Career Opportunities			Concept Committee Meeting
6:00		in HIV Vaccine & Prevention Research			(5:30 - 6:30 pm)
6:30		(5:00 - 7:00 pm)			
7:00					
7:30					
8:00					
8:30					
9:00					
9:30					



KEY

Plenary

Open Session

**Closed Session** 

Meals and Breaks

Live Streaming

Interpretation

## THURSDAY, MAY 2ND

TIME	REGENCY BALLROOM	EMPIRE BALLROOM	PALLADIAN BALLROOM	HAMPTON ROOM	EXECUTIVE ROOM
6:30					
7:00		• *			
7:30		CER Breakout Session (7:15 - 8:15 am)	HVTN 301 Site Meeting		HVTN 312 Site Meeting
8:00	• * Non-Technical Day 2 (8:15 - 8:30 am)		(7:15 - 8:15 am)		(7:15 - 8:15 am)
8:30	• * THE HVTN AT 25 YEARS OF AGE				
9:00	• * Plenary 3:				
9:30	Data Forum 1 (8:45 - 10:15 am)				
10:00	, , , , , , , , , , , , , , , , , , ,				Microsoft Teams
10:30	•*				Refresher Drop-In (10:15 - 10:45 am)
11:00	Plenary 4:				
11:30	Combining T & B cell Immunity				
12:00	(10:45 - 12:45 pm)				
12:30	• * Translational Science Award				Microsoft Teams Refresher Drop-In
1:00		Breaking Down the Science Luncheon	Road to Combo-AMP Update	Clinic Coordinator Breakout Session	HVTN 303 Writing Team Meeting
1:30		(1:00 - 2:00 pm)	(1:00 - 2:00 pm)	(1:00 - 2:00 pm)	(1:00 - 2:00 pm)
2:00	• <b>*</b> HVTN AWARDS (2:00 - 2:20 pm)				
2:30	• *				
3:00	Plenary 5:				
3:30	RAMP Scholar Poster Discussion (2:20 - 5:00 pm)				Microsoft Teams Refresher Drop-In
4:00	,				(3:45 - 4:10 pm)
4:30					
5:00		<b>*</b>			Sortase-conjugated CH505 Nanoparticle Vaccine Regimen
5:30		HVTN Faith Initiative Fireside Chat (5:00 - 6:30 pm)			(5:00 - 6:00 pm)
6:00	● ★ Plenary 6: Poster Session Flash Talks (6:00 - 6:30 pm)				
6:30	Poster Reception	●★ HVTN 606 Site Meeting			
7:00	(6:30 - 7:30 pm)	(6:30 - 7:30 pm)			
7:30					
8:00			SGC Dinner		
8:30			(7:30 - 9:30 pm)		
9:00					
9:30					

CONGRESSIONAL ROOM A & B	CABINET ROOM	FORUM ROOM	AMBASSADOR BALLROOM	BIRDCAGE WALK	WEST REGISTRATION DESK	TIME
						6:30
		CoVPN 3008 TB	Breakfast			7:00
HVTN Mentor Workshop (7:15 - 8:15 am)	Viral Escape from VRC01 Writing Team (7:15 - 8:15 am)	Substudy Protocol Team Meeting	Buffet			7:30
	(7.13 - 6.13 aiii)	(7:15 - 8:15 am)	(6:45 - 8:30 am)			8:00
						8:30
						9:00
						9:30
			Morning Break			10:00
			(10:15 - 10:45 am)			10:30
						11:00
					Open Registration & Badge Pick-Up	11:30
					(6:30 am – 6:30 pm)	12:00
						12:30
Protocol Chair & Co-Chair Interest Session (1:00 - 1:30 pm)	HVTN 300 Writing Team Meeting		Lunch Buffet			1:00
Scientific Leadership Development Program Overview (1:30 - 2:00 pm)	(1:00 - 2:00 pm)		(12:45 – 2:00 pm)			1:30
						2:00
						2:30
						3:00
			Afternoon Break			3:30
			(3:45 – 4:10 pm)			4:00
						4:30
		HxB2 Writing Team Core Concept Call				5:00
		(5:00 - 6:00 pm)		HVTN Lab Center Gathering (5:00 - 6:30 pm)		5:30
						6:00
HVTN Lab Center Leadership Group	Community Engagement R01 Planning & Logistics (US Sites)					6:30
(6:30 - 7:30 pm)	(US Sites) (6:30 - 7:30 pm)					7:00
						7:30
						8:00
						8:30
						9:00
						9:30

KEY

Open Session

Closed Session

Meals and Breaks

Live Streaming

\* Interpretation

## FRIDAY, MAY 3RD

TIME	REGENCY BALLROOM	EMPIRE BALLROOM	PALLADIAN BALLROOM	HAMPTON ROOM	EXECUTIVE ROOM
6:30					
7:00		Community Wrap-Up Session	HVTN 807-ATI		
7:30		(7:00 – 8:00 am)	Site Meeting (7:00 – 8:00 am)		
8:00	• * Plenary 7: Scientific Leadership Development (SLD)				
8:30	Presentations (8:00 – 9:05 am)				
9:00	• * HIV Vaccine Trials Network				
9:30	Wizard Award (9:05 – 9:35 am)  ◆ ★				
10:00	Plenary 8: Data Forum 2				
10:30	(9:35 – 11:00 am)				
11:00	• *	l			
11:30	Plenary 9: Meeting Wrap-Up				
12:00	(11:15 am – 12:30 pm)				
12:30					
1:00					
1:30					
2:00					
2:30					
3:00					
3:30					
4:00					
4:30					
5:00					
5:30					
6:00					
6:30					
7:00					
7:30					
8:00					
8:30					
9:00					
9:30					

